• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Allogene Therapeutics Inc. (Amendment)

    2/14/24 4:36:10 PM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALLO alert in real time by email
    SC 13G/A 1 d751841dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)

     

     

    ALLOGENE THERAPEUTICS, INC.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    019770 10 6

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 019770 10 6    13G    Page 2 of 9 Pages

     

     1   

     Names of Reporting Persons

     

     Arie Belldegrun, M.D.

     2  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☐

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     United States of America and Israel

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5   

     Sole Voting Power

     

     3,192,581 Shares (1)

       6  

     Shared Voting Power

     

     6,703,323 Shares (2)

       7  

     Sole Dispositive Power

     

     3,192,581 Shares (1)

       8  

     Shared Dispositive Power

     

     6,703,323 Shares (2)

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     9,895,903 Shares

    10  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     ☐

    11  

     Percent of Class Represented by Amount in Row (9)

     

     5.8% (3)

    12  

     Type of Reporting Person

     

     IN

     

    (1)

    Includes 2,847,489 shares of common stock issuable within 60 days of December 31, 2023 upon the exercise of stock options held by the Reporting Person and 142,150 shares issuable upon the settlement of Restricted Stock Units held by the Reporting Person that are releasable within 60 days of December 31, 2023.

    (2)

    Includes (a) 4,710,120 shares of common stock beneficially owned by Bellco Legacy IV LLC, a limited liability company managed by Dr. Belldegrun and Rebecka Belldegrun, (b) 195,039 shares of common stock beneficially owned by Bellco Legacy LLC, a limited liability company owned and managed by trusts controlled by Dr. Belldegrun and Rebecka Belldegrun and (c) 1,798,163 shares of common stock beneficially owned by Vida Ventures LLC (Vida), of which VV Manager LLC is the manager, of which Dr. Belldegrun is a Senior Managing Director. Dr. Belldegrun disclaims beneficial ownership of the shares held by Vida, except to the extent of any pecuniary interest therein.

    (3)

    This percentage is calculated based on 168,276,662 shares of common stock outstanding as of October 31, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed on November 2, 2023.


    CUSIP No. 019770 10 6    13G    Page 3 of 9 Pages

     

     1   

     Names of Reporting Persons

     

     Bellco Legacy IV, LLC

     2  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☐

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5   

     Sole Voting Power

     

     0 Shares

       6  

     Shared Voting Power

     

     4,710,120 Shares

       7  

     Sole Dispositive Power

     

     0 Shares

       8  

     Shared Dispositive Power

     

     4,710,120 Shares

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     4,710,120 Shares

    10  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     ☐

    11  

     Percent of Class Represented by Amount in Row (9)

     

     2.8% (1)

    12  

     Type of Reporting Person

     

     OO

     

    (1)

    This percentage is calculated based on 168,276,662 shares of common stock outstanding as of October 31, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed on November 2, 2023.


    CUSIP No. 019770 10 6    13G    Page 4 of 9 Pages

     

     1   

     Names of Reporting Persons

     

     Bellco Legacy LLC

     2  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☐

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5   

     Sole Voting Power

     

     0 Shares

       6  

     Shared Voting Power

     

     195,039 Shares

       7  

     Sole Dispositive Power

     

     0 Shares

       8  

     Shared Dispositive Power

     

     195,039 Shares

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     195,039 Shares

    10  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     ☐

    11  

     Percent of Class Represented by Amount in Row (9)

     

     0.1% (1)

    12  

     Type of Reporting Person

     

     OO

     

    (1)

    This percentage is calculated based on 168,276,662 shares of common stock outstanding as of October 31, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed on November 2, 2023.


    CUSIP No. 019770 10 6    13G    Page 5 of 9 Pages

     

     1   

     Names of Reporting Persons

     

     Vida Ventures LLC

     2  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☐

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     Nevada

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5   

     Sole Voting Power

     

     0 Shares

       6  

     Shared Voting Power

     

     1,798,163 Shares

       7  

     Sole Dispositive Power

     

     0 Shares

       8  

     Shared Dispositive Power

     

     1,798,163 Shares

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     1,798,163 Shares

    10  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     ☐

    11  

     Percent of Class Represented by Amount in Row (9)

     

     1.1% (1)

    12  

     Type of Reporting Person

     

     OO

     

    (1)

    This percentage is calculated based on 168,276,662 shares of common stock outstanding as of October 31, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed on November 2, 2023.


    CUSIP No. 019770 10 6    13G    Page 6 of 9 Pages

     

    Item 1(a).

    Name of Issuer:

    Allogene Therapeutics, Inc.

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    210 East Grand Avenue

    South San Francisco, CA 94080

     

    Item 2(a).

    Names of Persons Filing:

    Arie Belldegrun, M.D.

    Bellco Legacy IV LLC

    Bellco Legacy LLC

    Vida Ventures LLC

     

    Item 2(b).

    Address of Principal Business Office, or, if none, Residence:

    The address of Arie Belldegrun, M.D. is:

    10100 Santa Monica Blvd., 15th Floor, Los Angeles, CA 90067

    The address of Bellco Legacy IV LLC and Bellco Legacy LLC is:

    10100 Santa Monica Blvd., 15th Floor, Los Angeles, CA 90067

    The address of Vida Ventures LLC is:

    40 Broad Street, #201, Boston, MA 02109

     

    Item 2(c).

    Citizenship:

    Arie Belldegrun: USA and Israel

    Bellco Legacy IV LLC: Delaware

    Bellco Legacy LLC: Delaware

    Vida Ventures LLC: Nevada

     

    Item 2(d).

    Title of Class of Securities:

    Common Stock

     

    Item 2(e).

    CUSIP No.:

    019770 10 6

     

    Item 3.

    Not Applicable.


    CUSIP No. 019770 10 6    13G    Page 7 of 9 Pages

     

    Item 4.

    Ownership

    The information requested hereinafter is set forth in items 5 through 9 and 11 of the cover page to this Schedule 13G. Ownership is stated as of December 31, 2023. This percentage is calculated based on 168,276,662 shares of common stock outstanding as of October 31, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed on November 2, 2023.

     

    Reporting Person

       Shares Held
    Directly
         Sole
    Voting
    Power
         Shared
    Voting
    Power
         Sole
    Dispositive
    Power
         Shared
    Dispositive
    Power
         Beneficial
    Ownership
         Percentage
    of Class(1)
     

    Arie Belldegrun

         3,192,581        3,192,581        6,703,323        3,192,581        6,703,323        9,895,903        5.8 % 

    Bellco Legacy IV, LLC

         4,710,120        0        4,710,120        0        4,710,120        4,710,120        2.8 % 

    Bellco Legacy LLC

         195,039        0        195,039        0        195,039        195,039        0.1 % 

    Vida Ventures LLC

         1,798,163        0        1,798,163        0        1,798,163        1,798,163        1.1 % 

     

    (1)

    This percentage is calculated based on 168,276,662 shares of common stock outstanding as of October 31, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed on November 2, 2023.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof, the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☐

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person

    Not applicable

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

    Not applicable

     

    Item 8.

    Identification and Classification of Members of the Group

    Not applicable

     

    Item 9.

    Notice of Dissolution of Group

    Not applicable


    CUSIP No. 019770 10 6    13G    Page 8 of 9 Pages

     

    Item 10.

    Certifications

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 14, 2024

     

    /s/ Arie Belldegrun
    Arie Belldegrun, M.D.

     

    Bellco Legacy IV LLC
    By:   /s/ Arie Belldegrun
    Name:   Arie Belldegrun, Manager

     

    Bellco Legacy LLC
    By:   /s/ Arie Belldegrun
    Name:   Arie Belldegrun, Manager

    Vida Ventures LLC

    By: VV Manager LLC, its Manager

    By:   /s/ Arie Belldegrun
    Name:   Arie Belldegrun, Senior Managing Director

     

    Get the next $ALLO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALLO

    DatePrice TargetRatingAnalyst
    3/14/2025$5.00Mkt Perform → Mkt Outperform
    Citizens JMP
    8/8/2024$13.00 → $11.00Outperform
    Oppenheimer
    5/31/2024$11.00Overweight
    Piper Sandler
    1/5/2024Mkt Outperform → Mkt Perform
    JMP Securities
    1/5/2024Buy → Neutral
    Guggenheim
    12/8/2023$7.00Buy
    Citigroup
    12/8/2023Buy
    Citigroup
    6/26/2023$28.00Outperform
    Oppenheimer
    More analyst ratings

    $ALLO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update

      Conference Call and Webcast Scheduled for May 13, 2025 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report the first quarter 2025 financial results and provide a business update on May 13, 2025, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET. Listen-Only WebcastThe listen-only webcast will be made available on the Company's website at www.all

      5/6/25 8:30:00 AM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

      SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will present updated data from the completed Phase 1 TRAVERSE trial of ALLO-316 in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 2 in Chicago, Illinois. The trial evaluated ALLO-316 in patients with advanced or metastatic renal cell carcinoma (RCC) who had progressed following immune checkpoint inhibitor and VEGF-targeted therapies. In addition, a t

      4/23/25 10:12:13 AM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

      Designations Follow Recent Investigational New Drug (IND) Application Clearance for the RESOLUTION Basket Study of ALLO-329 in RheumatologyDual CD19/CD70 CAR T Specifically Designed to Enhance Therapeutic Benefit, Expanding Treatment Potential Across a Range of Autoimmune IndicationsLeverages Proprietary Dagger® Technology to Reduce or Eliminate Lymphodepletion, Potentially Expanding Access to a Broader Patient PopulationPhase 1 RESOLUTION Trial Initiation Planned for Mid-2025 with Initial Proof-of-Concept by Year-End 2025 SOUTH SAN FRANCISCO, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the develop

      4/7/25 8:30:00 AM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALLO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Belldegrun Arie was granted 344,828 shares and bought $4,999,997 worth of shares (1,724,137 units at $2.90) (SEC Form 4)

      4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)

      5/20/24 9:33:32 PM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Parker Geoffrey M. bought $683 worth of shares (190 units at $3.60), increasing direct ownership by 0.02% to 819,590 units (SEC Form 4)

      4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)

      3/6/24 9:52:06 PM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALLO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, Finance Yoshiyama Annie sold $13,537 worth of shares (9,601 units at $1.41), decreasing direct ownership by 7% to 130,663 units (SEC Form 4)

      4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)

      4/23/25 5:28:51 PM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Chang David D sold $91,469 worth of shares (46,668 units at $1.96), decreasing direct ownership by 0.88% to 5,276,569 units (SEC Form 4)

      4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)

      3/18/25 5:30:50 PM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVP, Chief Technical Officer Beneski Benjamin Machinas sold $10,839 worth of shares (5,488 units at $1.98), decreasing direct ownership by 2% to 218,507 units (SEC Form 4)

      4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)

      3/18/25 5:28:04 PM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALLO
    Leadership Updates

    Live Leadership Updates

    See more
    • Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors

      SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Alison Moore, Ph.D., as an independent member of its Board of Directors. Dr. Moore brings over 25 years of executive experience in the biotechnology and pharmaceutical industry, including an extensive background in cell therapy manufacturing. She currently serves as Chief Technical Officer (CTO) of Codexis Inc. (NASDAQ:CDXS), a leading enzyme engineering company, and was the former CTO of Allog

      10/22/24 4:05:00 PM ET
      $ALLO
      $ARTV
      $CDXS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Major Chemicals
      Industrials
    • Allogene Therapeutics Appoints Geoffrey Parker as Chief Financial Officer

      SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, has appointed Geoffrey Parker as Executive Vice President, Chief Financial Officer. Mr. Parker will oversee the Company's financial operations and business strategy and will serve as a member of the Leadership Team. "Geoff's extensive experience in biotechnology across all aspects of finance and business development strategy will be of tremendous value to Allogene as we advance our critical pipeline assets and explore new opportunities," said David Chang, M.D., Ph.D.

      10/16/23 8:30:00 AM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Allogene Therapeutics Appoints Earl Douglas as General Counsel

      SOUTH SAN FRANCISCO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that Earl Douglas has been appointed as General Counsel. Mr. Douglas will oversee all aspects of the Company's legal function and serve as a member of the Leadership Team. "We are excited to welcome Earl who brings a tenure of experience guiding publicly-traded biotech companies on complex legal issues, corporate strategy and transactions," said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene. "I also want to th

      8/14/23 8:30:00 AM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALLO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Allogene Therapeutics Inc.

      SC 13G/A - Allogene Therapeutics, Inc. (0001737287) (Subject)

      11/12/24 1:26:25 PM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Allogene Therapeutics Inc.

      SC 13G - Allogene Therapeutics, Inc. (0001737287) (Subject)

      11/4/24 10:57:36 AM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Allogene Therapeutics Inc. (Amendment)

      SC 13G/A - Allogene Therapeutics, Inc. (0001737287) (Subject)

      2/14/24 4:36:10 PM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALLO
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Allogene Therapeutics Inc.

      SCHEDULE 13G/A - Allogene Therapeutics, Inc. (0001737287) (Subject)

      5/9/25 5:49:01 PM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Allogene Therapeutics Inc.

      SCHEDULE 13G/A - Allogene Therapeutics, Inc. (0001737287) (Subject)

      5/9/25 5:30:51 PM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by Allogene Therapeutics Inc.

      144 - Allogene Therapeutics, Inc. (0001737287) (Subject)

      3/14/25 4:57:40 PM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALLO
    Financials

    Live finance-specific insights

    See more
    • Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update

      Conference Call and Webcast Scheduled for May 13, 2025 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report the first quarter 2025 financial results and provide a business update on May 13, 2025, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET. Listen-Only WebcastThe listen-only webcast will be made available on the Company's website at www.all

      5/6/25 8:30:00 AM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

      Momentum Builds Across Programs with Key Data Milestones Expected in 2025Cemacabtagene Ansegedleucel (Cema-Cel): First-Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Ongoing Pivotal Phase 2 ALPHA3 Trial Advancing with Site Activation and Patient EnrollmentLymphodepletion Selection and Futility Analysis Anticipated Around Mid-2025Primary EFS Data Expected Around YE 2026 with Potential BLA Submission in 2027 ALLO-329 in Autoimmune Disease (AID) Secured Investigational New Drug (IND) FDA Clearance for the RESOLUTION Basket Trial in RheumatologyTrial Initiation Targeted for Mid-2025; Proof-of-Concept Data Expected Around YE 2025 ALLO-316 in Renal Cell Carcinoma (RCC) Presented Posi

      3/13/25 4:02:00 PM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

      Conference Call and Webcast Scheduled for March 13, 2025 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report the fourth quarter and full year 2024 financial results and provide a business update on March 13, 2025, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET. Listen-Only WebcastThe listen-only webcast will be made available on the Com

      3/3/25 8:30:00 AM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALLO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Allogene upgraded by Citizens JMP with a new price target

      Citizens JMP upgraded Allogene from Mkt Perform to Mkt Outperform and set a new price target of $5.00

      3/14/25 7:12:11 AM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Oppenheimer resumed coverage on Allogene with a new price target

      Oppenheimer resumed coverage of Allogene with a rating of Outperform and set a new price target of $11.00 from $13.00 previously

      8/8/24 7:10:59 AM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Piper Sandler initiated coverage on Allogene with a new price target

      Piper Sandler initiated coverage of Allogene with a rating of Overweight and set a new price target of $11.00

      5/31/24 7:35:04 AM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care